Džidić-Krivić Amina, Kusturica Jasna, Sher Emina Karahmet, Selak Nejra, Osmančević Nejra, Karahmet Farhat Esma, Sher Farooq
Zenica Cantonal Hospital, Zenica, Bosnia and Herzegovina.
International Society of Engineering Science and Technology, Nottingham, UK.
Drug Metab Rev. 2023 Feb-May;55(1-2):126-139. doi: 10.1080/03602532.2023.2186313. Epub 2023 Mar 14.
Gut microbiota is known as unique collection of microorganisms (including bacteria, archaea, eukaryotes and viruses) that exist in a complex environment of the gut. Recently, this has become one of the most popular areas of research in medicine because this plays not only an important role in disease development, but gut microbiota also influences drug pharmacokinetics. These alterations in drug pharmacokinetic pathways and drug concentration in plasma and blood often lead to an increase in the incidence of toxicological events in patients. This review aims to present current knowledge of the most commonly used drugs in clinical practice and their dynamic interplay with the host's gut microbiota as well as the mechanisms underlying these metabolic processes and the consequent effect on their therapeutic efficacy and safety. These new findings set a foundation for the development of personalized treatments specific to each metabolism, maximizing drugs' therapeutic effects and minimizing the side effects because they are one of the major limiting factors in treating patients.
肠道微生物群是指存在于肠道复杂环境中的独特微生物集合（包括细菌、古菌、真核生物和病毒）。最近，这已成为医学研究中最热门的领域之一，因为它不仅在疾病发展中起重要作用，而且肠道微生物群还会影响药物的药代动力学。药物药代动力学途径以及血浆和血液中药物浓度的这些变化通常会导致患者毒理学事件发生率增加。本综述旨在介绍临床实践中最常用药物的现有知识，以及它们与宿主肠道微生物群的动态相互作用，以及这些代谢过程的潜在机制及其对治疗效果和安全性的影响。这些新发现为开发针对每种代谢的个性化治疗奠定了基础，最大限度地提高药物的治疗效果并将副作用降至最低，因为副作用是治疗患者的主要限制因素之一。
